{"filings":[{"id":780043,"accession_number":"0001213900-26-063575","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-06-01T21:00:15+00:00","items":["3.01"],"status":"ready","headline":"iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 29, 2026 for non-compliance with minimum stockholders' equity of $2.5M; equity was $814,038.","Company has 45 calendar days to submit a compliance plan to Nasdaq; if accepted, may get up to 180-day extension.","Trading of common stock (ISPC) continues on Nasdaq Capital Market with no immediate effect.","Company intends to submit a plan but warns no assurance Nasdaq will accept or that compliance will be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748916,"accession_number":"0001213900-26-062937","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-05-29T21:13:12+00:00","items":["5.07"],"status":"ready","headline":"iSpecimen stockholders elect Class I director, ratify auditor, approve 2025 incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Arphing (Tommy) Lee elected Class I director with 562,361 votes FOR, 150,431 WITHHELD.","Bush & Associates CPA LLC ratified as independent auditor for FY2025: 2,424,420 FOR, 155,256 AGAINST.","iSpecimen 2025 Stock Incentive Plan approved: 461,073 FOR, 186,740 AGAINST, 64,979 ABSTAIN.","Quorum of 2,979,059 shares (35.14%) present at May 29, 2026 reconvened annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":70282,"accession_number":"0001213900-26-055912","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-05-13T21:00:25+00:00","items":["1.01","3.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 488,281 shares and pre-funded warrants for gross proceeds of ~$2.5M at $5.12 per share (or $5.1199 for warrants).","Net proceeds to be used for working capital, including up to $900,000 in marketing expenses.","Nasdaq confirmed compliance with $1.00 minimum bid price requirement on May 12, 2026 after 10 consecutive days above $1.","Annual meeting adjourned multiple times since Dec 31, 2025 due to lack of quorum; next adjourned to May 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93623,"accession_number":"0001213900-26-051013","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"iSpecimen effectuates 1-for-40 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective 4:30 p.m. ET on April 27, 2026; trading on split-adjusted basis began April 28.","Shares outstanding reduced from 52,639,796 to approximately 1,316,032; no fractional shares issued (rounded up).","Board also ratified prior 1:20 reverse split (Sept 2024) via Certificate of Validation under Delaware law.","CUSIP changed to 45032V306; symbol remains ISPC on Nasdaq Capital Market.","Split intended to increase per-share price to attract institutional investors and meet minimum bid listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93622,"accession_number":"0001213900-26-042976","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen annual meeting adjourned five times due to lack of quorum; next attempt May 8, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting convened Dec 31, 2025; quorum not present, adjourned.","Reconvened Jan 23, Feb 13, Mar 13, Apr 10, 2026; no quorum each time.","Next reconvened meeting scheduled for May 8, 2026 at 9:00 a.m. ET.","Record date remains Nov 3, 2025; no changes to proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93621,"accession_number":"0001213900-26-042468","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen reduces biospecimen shipping time by up to 85% with direct-to-customer model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Domestic shipments now delivered in 1-2 days vs. 7-14 days previously, a 70-85% reduction.","Streamlined model reduces reliance on central hub, lowering overall shipping costs through fewer handoffs.","Expanded international partnerships in Europe and Eastern Europe for rare biospecimens, improving turnaround times.","CEO Katie Field notes positive customer feedback on delivery speed, quality, and care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105409,"accession_number":"0001213900-26-027736","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen annual meeting adjourned repeatedly due to lack of quorum; next adjournment April 10, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting originally convened Dec 31, 2025; no quorum, adjourned.","Reconvened Jan 23, 2026, Feb 13, 2026, and Mar 13, 2026; quorum still not present.","Next adjournment set for Apr 10, 2026 at 9:00 AM ET.","Record date remains Nov 3, 2025; proposals unchanged from proxy statement filed Nov 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105408,"accession_number":"0001213900-26-019354","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Siyun Yang resigns from iSpecimen board effective Feb 17, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation not due to any disagreement with the Company on operations, policies or practices.","Yang served as independent director since February 2025.","She was a member of the Audit Committee and the Nominating and Corporate Governance Committee.","No replacement has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105407,"accession_number":"0001213900-26-017963","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen adjourns annual meeting three times due to no quorum; next attempt March 13, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dec 31, 2025 annual meeting adjourned for lack of quorum.","Reconvened Jan 23, 2026 and Feb 13, 2026, both also lacked quorum.","Next reconvened meeting scheduled March 13, 2026; record date remains Nov 3, 2025.","No changes to proposals from the original proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105406,"accession_number":"0001213900-26-013265","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen completes SalesStack Milestone 2, launches live marketplace; procures 500 influenza samples","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Milestone 2 achieved: end-to-end system integration, legacy data migration, live marketplace at mp.ispecimen.com.","AI-assisted demand-supply matching now live; legacy AWS costs to be reduced from infrastructure sunset.","Collected 500 influenza swab samples in a few weeks for a customer research project.","Consistent CSF supply maintained; increased customer demand for FFPE and fresh frozen tissue.","Customer praised urine specimen quality and documentation, plans to cite iSpecimen in publications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105405,"accession_number":"0001213900-26-008215","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen adjourns annual meeting twice due to lack of quorum; next attempt Feb 13, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting adjourned on Dec 31, 2025 and again on Jan 23, 2026 due to no quorum.","Reconvened meeting scheduled for February 13, 2026; record date remains November 3, 2025.","Stockholders are asked to vote on proposals per the definitive proxy filed Nov 21, 2025.","Continued lack of quorum may delay shareholder decisions on key proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105401,"accession_number":"0001213900-26-005138","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K/A","filed_at":"2026-01-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"iSpecimen amends Series C Preferred Stock terms to add anti-dilution adjustment for reverse splits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Jan 16, 2026, iSpecimen filed amended Certificate of Designation for Series C Convertible Non-Voting Preferred Stock.","Amendment adjusts Conversion Price and Floor Price proportionately on any reverse stock split or share combination.","Approved by holders of majority of outstanding Series C Preferred Stock per Section 23 of original designation.","No other changes to terms, preferences, or privileges of Series C Preferred Stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105404,"accession_number":"0001213900-26-001264","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen 2025 annual meeting adjourned due to lack of quorum; reconvenes Jan 23, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting held Dec 31, 2025 adjourned because quorum was not achieved.","Meeting reconvened to Jan 23, 2026; record date remains Nov 3, 2025.","Company seeks additional time for stockholders to vote on proxy proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105403,"accession_number":"0001213900-26-001257","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"iSpecimen pays IR Agency $2M upfront for 4-month marketing consulting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate cash fee of $2,000,000 paid upon execution from Series C Preferred Stock placement proceeds.","Four-month term beginning December 31, 2025, for marketing, advertising, and digital community-building services.","Consultant is not a broker-dealer and will not solicit investors or effect securities transactions.","Agreement may be terminated with or without cause; fees deemed earned upon receipt and non-refundable if client terminates.","Company funded the fee from net proceeds of its private placement of Series C Convertible Non-Voting Preferred Stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105402,"accession_number":"0001213900-26-000496","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"iSpecimen raises $5.5M via Series C Convertible Preferred Stock at $800/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 6,875 shares of Series C Convertible Non-Voting Preferred at $800/share for $5.5M aggregate.","Conversion price set at 85% of prior day's closing price, floor at $0.0681 per share.","Shares are senior to common on liquidation and carry no voting rights; registration rights granted.","E.F. Hutton acted as exclusive placement agent; lock-up agreements with officers/directors for 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121686,"accession_number":"0001213900-25-116663","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen regains Nasdaq compliance on stockholders' equity, matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 28, 2025 confirming compliance with continued listing requirements.","Previously disclosed deficiency on June 4, 2025 for minimum equity, market value, or net income.","Based on Q3 2025 10-Q showing stockholders' equity of $3,072,711, Staff determined compliance and closed matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121685,"accession_number":"0001213900-25-113708","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"iSpecimen receives Nasdaq deficiency notice for bid price below $1.00; cure deadline May 18, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Nov 19, 2025; stock continues trading under ISPC with no immediate delisting.","Company has 180 calendar days, until May 18, 2026, to regain compliance.","To cure, closing bid price must be at least $1.00 for ten consecutive business days.","If not cured by May 18, 2026, an additional 180-day period may be available if other listing criteria are met.","Options include a reverse stock split; failure to cure could lead to delisting and appeal rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121684,"accession_number":"0001213900-25-107647","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen appoints Katharyn Field as CEO, replacing Robert Bradley Lim; adds independent director Tommy Lee.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Katharyn Field appointed CEO, Secretary, and Treasurer effective Nov 7, 2025; she continues as President.","Robert Bradley Lim resigned as CEO, Secretary, Treasurer and from board; no disagreement cited.","Arphing (Tommy) Lee appointed as independent director, joining Audit and Nominating/Governance Committees.","Board committees reconstituted; Field now holds three officer titles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121683,"accession_number":"0001213900-25-104942","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"iSpecimen stockholders approve reverse stock split, authorized share increase, and equity line of credit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio from 1:10 to 1:100; Board to set exact ratio.","Authorized shares increased from 250M to 1B; 1,370,770 voted for.","Private financings up to >19.99% of shares at sub-minimum price approved for Nasdaq compliance.","Convertible securities amended to raise conversion price floor from 50% to 80% of lowest VWAP.","Equity line of credit approved allowing issuance >19.99% of shares at below-minimum price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138363,"accession_number":"0001213900-25-084497","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen approached by crypto companies for $200M Solana treasury initiative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["iSpecimen has been approached by several crypto firms for opportunities in tokenized real-world assets and top cryptocurrencies.","Company continues meetings to build a Solana-based treasury program of up to $200 million.","Plans to purchase SOL, including locked SOL at a discount, and stake holdings to generate yield.","Will fund treasury primarily from capital raised; intends to source external treasury management expertise.","Strategy includes HODL approach, staking, liquid staking tokenization, and limited spot trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138362,"accession_number":"0001213900-25-079167","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen completes Milestone 1 of digital transformation with Salestack platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed Milestone 1 installation of Salestack platform and modern infrastructure for iSpecimen Marketplace.","Milestone 1 focused on Infrastructure-as-Code, unified storage/workflows, and future-ready multi-cloud architecture.","Moving to Milestone 2 (Integration) to connect all business operations for end-to-end efficiency.","Expected benefits include improved reliability, enhanced security, and accelerated innovation cycles.","CEO Robert Lim states milestone sets stage for long-term shareholder value creation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138361,"accession_number":"0001213900-25-073069","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen plans $200M Solana-based digital asset treasury, hires BlockArrow","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["iSpecimen to build up to $200M corporate treasury reserve on Solana blockchain ecosystem.","Retained WestPark Capital as advisor; contracted BlockArrow for digital asset strategy and management.","Treasury will use cold storage, insured custody via Coinbase Custody, and institutional risk controls.","CEO Rob Lim says initiative aligns with decentralized infrastructure and digital asset future.","Company plans to diversify future digital treasury across high-performing crypto assets for liquidity and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138360,"accession_number":"0001213900-25-072070","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iSpecimen raises $1.75M in private placement of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$1.75M from 1,559,828 shares (or pre-funded warrants) at $1.122/share; closed August 4, 2025.","$500K of net proceeds allocated to marketing/advertising services from IR Agency LLC; remainder for working capital.","WestPark Capital acting as exclusive placement agent received 4% cash commission on gross proceeds.","Company to file resale registration statement within 15 calendar days of closing per Registration Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138359,"accession_number":"0001213900-25-067772","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iSpecimen closes $4M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,714,283 securities (1,482,644 shares + 4,231,639 pre-funded warrants) at $0.70/share for gross $4M.","Net proceeds of ~$3.53M after underwriting discounts and offering expenses; closed July 25, 2025.","Plans to use $1.5M for marketing/advertising via IR Agency LLC and $1M for software milestone with Sales Stack Solutions.","WestPark Capital acted as sole book-runner; offering made under effective Form S-1 (File 333-286958).","Pre-funded warrants exercisable immediately at $0.0001, with 4.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138358,"accession_number":"0001213900-25-062804","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"iSpecimen amends bylaws to reduce shareholder quorum to 34% from majority","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum threshold reduced from a majority to 34% of voting power.","Amendment adopted on July 9, 2025; Third Amended and Restated Bylaws filed.","No other changes to bylaws or fiscal year disclosed.","Governance change effective immediately upon adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155810,"accession_number":"0001213900-25-057284","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen directors Paolone and Brooks resign; Lau appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard J. Paolone resigned as director and Chairman effective June 18; no disagreement involved.","John L. Brooks III resigned as director effective June 18; he previously chaired the Audit Committee.","Anthony Lau appointed director effective June 20; also joins Audit, Compensation, and Nominating Committees.","Lau is CEO/CFO of Remington Resources; brings public company governance and financial reporting experience.","Board committees reorganized: Lau chairs Audit, Yang chairs Compensation, Dhaliwal chairs Nominating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155809,"accession_number":"0001213900-25-051593","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"iSpecimen receives Nasdaq delisting notice for failing to meet minimum stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 4, 2025 regarding non-compliance with Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.","As of March 31, 2025, stockholders' equity was $1,668,513, below the $2.5M threshold; no alternative listing criteria met.","Company has 45 days to submit a compliance plan; if accepted by Nasdaq, may receive up to 180-day extension to regain compliance.","If plan not accepted or compliance not regained, Nasdaq may delist the common stock; Company can appeal to a Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174281,"accession_number":"0001213900-25-022444","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"iSpecimen auditor Wolf & Company resigns; Bush & Associates appointed as new independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wolf & Company resigned as iSpecimen's auditor effective March 7, 2025.","Audit reports for FY2022 and FY2023 were unqualified; FY2023 included a going-concern explanatory paragraph.","No disagreements or reportable events between company and Wolf during those periods.","Audit Committee appointed Bush & Associates CPA LLC as new auditor on March 10, 2025 for FY2024.","No consultations with Bush & Associates on accounting principles or audit matters prior to appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174278,"accession_number":"0001213900-25-018804","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K/A","filed_at":"2025-02-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen finalizes President Field's employment; base salary $240,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $240,000, payable per standard payroll schedule.","Eligible for Stock Incentive Plan and standard fringe benefits for full-time employees.","At-will employment with 30-day notice period for termination by either party.","Employment contingent on background check and immigration documentation.","Company also requires execution of proprietary information and restrictive covenant agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174280,"accession_number":"0001213900-25-016309","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen appoints Katharyn Field as President; Siyun Yang joins board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Katharyn Field appointed President effective immediately; resigned from Board.","Siyun Yang appointed independent director, serving on Audit and Nominating committees, replacing Field.","Richard Paolone appointed Chair of the Board, replacing Field.","CEO Robert Bradley Lim remains; company does not anticipate operational disruption.","Compensation terms for Field as President not yet finalized; will be disclosed later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174279,"accession_number":"0001213900-25-004256","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iSpecimen secures suppliers for hMPV biospecimens amid China outbreak concerns","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["iSpecimen secured suppliers for human metapneumovirus (hMPV) biospecimens to meet potential demand.","Virus causing hospital overruns in China; no vaccine exists, raising pandemic fears.","Company expects researchers and vaccine developers to require hMPV specimens for study.","iSpecimen leverages its network of hospitals, labs, biobanks to procure specimens globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191227,"accession_number":"0001213900-24-113489","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen CEO Lim appointed Treasurer and Secretary effective Dec 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed CEO Robert Bradley Lim to additional roles of Treasurer and Secretary on December 27, 2024.","No changes to Mr. Lim's compensation or employment terms were made.","Appointment made by written consent of the Board under the company's bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191226,"accession_number":"0001213900-24-111290","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"iSpecimen names Yuying Liang CFO, unveils plan to expand cancer biospecimen procurement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Yuying Liang as CFO effective Dec 13, 2024; monthly fee of $25k under engagement with his professional corp.","Strategic 2025 initiatives focus on procuring high-demand cancer biospecimens through expanded partnerships.","Plans to establish referral program with international genomic sequencing partner; iSpecimen to be preferred provider.","Targeting new partnerships with U.S. cancer centers for domestic blood products, with 2025 launch.","Will expand portfolio with remnant biofluid offerings from recently partnered sites, including diagnostic codes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191225,"accession_number":"0001104659-24-128411","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iSpecimen's Next Day Quote Program drives 60% of purchase orders in Nov 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["30% of sales opportunities and 48% of all quotes were Next Day Quotes in November 2024.","60% of purchase orders came from NDQ; conversion rate for NDQ quotes is high.","NDQ program launched 2023; quotes can now be created within minutes using a search tool.","Management states NDQ drove an estimated 60% of sales in first six months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191224,"accession_number":"0001104659-24-128084","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"iSpecimen appoints Robert Lim as CEO and director effective Dec. 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Lim appointed CEO and board member; will provide strategic leadership and advisory services.","Annual fee of $270,000 payable to Lim's personal corporation, 1513932 B.C. Ltd., in monthly installments.","Lim is principal and co-founder of De Novo Law Corporation; brings legal, marketing, and business experience.","No familial relationships with other directors/officers; no reportable legal proceedings in past 10 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191223,"accession_number":"0001104659-24-116923","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen CEO/CFO/Treasurer Tracy Curley departs amid dispute with board over company direction","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tracy Curley's employment as CEO, CFO, and Treasurer ended Nov 8, 2024; parties dispute resignation vs termination.","Curley resigned from the board due to differences with the board regarding the future direction of the company.","Company is implementing steps to ensure a seamless leadership transition; successor not yet named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191222,"accession_number":"0001104659-24-113112","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iSpecimen raises ~$5M in public offering of stock and warrants; signs $2M IR agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 132,814 common shares and pre-funded warrants for up to 1,533,852 shares at $3.00 per share, grossing $4,998,464.","Proceeds to repay debt, fund potential acquisitions, and marketing/advertising; remainder for working capital.","Entered $2M investor relations agreement with IR Agency LLC for one-month term, extendable by mutual consent.","Placement agent WestPark Capital received 4.0% cash fee plus expense reimbursement.","Offering closed on October 31, 2024; securities registered under effective Form S-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191221,"accession_number":"0001104659-24-105451","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"iSpecimen ex-CIO files arbitration claim for $586,800; company defends","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Benjamin Bielak, former CIO, resigned July 14, 2024, and filed arbitration claim for unpaid bonuses/severance totaling $586,800 plus fees/interest.","Company believes claim without merit and intends to vigorously defend; no arbitrator selected yet.","Nasdaq notified iSpecimen on Oct 1, 2024 that it regained compliance with $1 minimum bid price after extended period.","Compliance restored after closing bid price above $1 from Sept 16-30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207691,"accession_number":"0001104659-24-102855","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"iSpecimen closes $1M note at 18% interest; lender secures three board seats","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1M senior note with 18% annual interest, maturing in 12 months; net proceeds $960,000 after $40,000 placement fee.","Three directors (Gullans, Mock, Graham) resigned; lender-designated directors Paolone, Dhaliwal, Field appointed effective Sept 25, 2024.","Additional $1M revolving credit line available upon filing of a registration statement for a $5M+ public offering.","New chairperson Katie Field; Paolone and Dhaliwal also join board committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207690,"accession_number":"0001104659-24-098955","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"iSpecimen to effect 1-for-20 reverse stock split on Sep 13, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1:20, effective 4:30 p.m. ET Sep 13; trading on split-adjusted basis begins Sep 16.","Board approved ratio on Aug 19, 2024, after stockholders authorized a 1:10 to 1:20 range on Jul 19.","Purpose: increase per-share price to attract institutional investors and maintain Nasdaq minimum bid listing.","All outstanding options, warrants, and RSUs proportionally adjusted; fractional shares rounded up.","Stock symbol remains ISPC on Nasdaq; new CUSIP 45032V207; Broadridge acting as exchange agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207689,"accession_number":"0001104659-24-086130","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"iSpecimen Q2 revenue up 76% to $2.86M; net loss narrows to $2.11M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.86M (+76% YoY); net loss $2.11M ($0.19/sh) vs $3.5M loss ($0.39/sh) in Q2 2023.","Hired Brielan Smiechowski as SVP of Sales & Business Development.","Next Day Quotes conversion rate 58% to purchase orders.","Cash and securities $2.15M as of June 30, 2024, down from $5.01M at Dec 31, 2023.","Supplier organizations reduced to 105 from 243 at year-end 2023."],"consensus_eps_estimate":-228.48,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":5153672.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207688,"accession_number":"0001104659-24-081547","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"iSpecimen stockholders authorize reverse split; director Ross resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Andrew L. Ross resigns effective July 25, 2024; no disagreement with management.","Stockholders approved amendment to authorize reverse stock split at ratio 1:10 to 1:20, at Board's discretion.","Tracy Curley and Elizabeth A. Graham elected as Class III directors for three-year terms.","Wolf & Company ratified as independent auditor for FY2024.","All proposals passed; reverse split filing timing at Board's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207687,"accession_number":"0001104659-24-078338","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"iSpecimen CIO and Secretary Benjamin Bielak resigns effective July 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Benjamin Bielak resigns as Chief Information Officer and Secretary.","Resignation effective July 15, 2024.","Company received written notice on July 5, 2024.","No successor named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207686,"accession_number":"0001104659-24-077817","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"iSpecimen downsizes office footprint 74% with new Woburn lease, termination of Lexington lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 5-year lease for ~2,273 sq ft in Woburn, base rent $72,736/year ($6,061/month) starting Sept 1, 2024.","Terminated Lexington lease (8,835 sq ft) effective Aug 31, 2024; paid $5,131.27 termination fee.","Office space reduction of ~74% from 8,835 to 2,273 sq ft, signaling cost-cutting.","Rent adjusts annually with CPI (Boston) up to 5% cap; security deposit of $12,122.","One-time option to extend lease for an additional 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225156,"accession_number":"0001104659-24-063018","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen sets 2024 annual meeting for July 19; record date June 3, proposal deadline May 27","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for July 19, 2024; record date for voting is June 3, 2024.","Meeting is more than 30 days after 2023 meeting anniversary; prior proposal deadlines no longer apply.","Stockholder proposals for proxy inclusion under Rule 14a-8 due by May 27, 2024.","Director nominations and other non-proxy proposals also due by May 27, 2024.","All proposals must be sent to iSpecimen Corporate Secretary at Lexington, MA address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225155,"accession_number":"0001104659-24-057770","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"iSpecimen Q1 revenue down 22% to $2.29M; net loss widens to ($0.32)/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.29M vs $2.95M YoY; specimen count fell 39% to 5,241, offset by 28% higher ASP ($437).","Net loss $2.90M ($0.32/share) vs $2.43M loss ($0.27/share) in Q1 2023; G&A up 16% to $2.10M.","Cash and securities $2.56M at Mar 31, down from $5.01M at Dec 31, 2023; ATM offering up to $1.5M.","Next Day Quotes reached 40% of all quotes; conversion rate on NQ quotes hit 91% (vs 32% in Q4 2023).","Supplier network trimmed to 140 from 243; customer count grew to 600+ (up 66 YoY)."],"consensus_eps_estimate":-220.32,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":2289993.0,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225154,"accession_number":"0001104659-24-046294","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"iSpecimen receives Nasdaq extension to Oct 7, 2024 to regain $1 minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq second 180-day compliance period through Oct 7, 2024 for minimum bid price.","Must have closing bid price ≥ $1 for 10 consecutive business days to regain compliance.","If compliance not met by Oct 7, 2024, Nasdaq will delist ISPC; company may appeal.","Initial 180-day period ended April 8, 2024 without regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244385,"accession_number":"0001104659-24-039021","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"iSpecimen appoints Elizabeth A. Graham to Board of Directors, filling vacancy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth A. Graham appointed as Class III director effective March 21, 2024, to fill vacancy from Joseph J. Basile's resignation.","Ms. Graham has experience in early-stage tech, ecommerce, and telecommunications; most recently COO of Indigo Ag Inc.","Board determined she is independent under Nasdaq rules; she will serve on nominating and corporate governance committee.","She will receive standard nonemployee director compensation pro-rated and enter into indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244384,"accession_number":"0001104659-24-034321","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"iSpecimen FY2023 revenue $9.93M (-4.5% YoY), net loss $11.1M; cash burn improves to $657K in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.93M vs $10.40M in 2022; specimen count fell 11% to 24,565 but ASP rose 7% to $404.","Net loss $11.10M ($1.23/sh) vs $10.2M ($1.16/sh); cash ended at $5.01M, down from $15.31M.","Q4 cash burn $657K, down from $4.29M in Q1; quote-to-PO conversion rose 39% vs prior quarters.","Record monthly revenue of ~$1.7M in Dec 2023; over 600 customer orgs and 7,428 registered users.","Entered ATM offering up to $1.5M on March 5, 2024 for additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244383,"accession_number":"0001104659-24-030807","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"iSpecimen enters ATM equity offering agreement for up to $1.5M with Rodman & Renshaw","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters At the Market Offering Agreement with Rodman & Renshaw LLC as sales agent for up to $1.5M of common stock.","Agent receives 3.0% commission on gross sales price; sales made at market prices on Nasdaq.","Agreement allows company to sell shares from time to time; no obligation to sell any shares.","Prospectus supplement filed under existing S-3 registration statement (File No. 333-265976) effective July 12, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4283683.965671641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-05T23:59:59+00:00|244383"}